Related Experiment Videos
Moxalactam in the therapy of serious infections
Abstract:
Sixty-seven patients were treated with moxalactam in a noncomparative trial of hospitalized patients; 32 had endometritis or chorioamnionitis, 12 had skin and soft tissue infections, 5 had osteomyelitis, 5 had pneumonia, 5 had urinary tract infections, 4 had arthritis, 2 had sepsis from an unknown source, 1 had endocarditis, and 1 had peritonitis. Bacteremia was present in 12 of these patients. Patients were given 3 to 12 g of moxalactam per day (mean, 6.24 g/day) in divided doses every 6 to 8 h. Seven patients were given intramuscular treatment for 3 to 20 days for part or all of their therapy. The rest were given intravenous treatment exclusively. Treatment was continued for 2 to 42 days (mean, 10 days). The dose and the duration of therapy were determined by the type of infection and the response of each patient. There were four treatment failures and one enterococcal-clostridial superinfection. Moxalactam was well tolerated. Allergic reactions led to the discontinuation of the antibiotic in three patients. Prolonged prothrombin and partial thromboplastin times were observed in 2 of 11 patients tested; in both instances in patients had severe underlying diseases, including malnutrition and alcoholism. Pain on intramuscular injection was noted in two patients receiving 1,500 mg, but not in five receiving a lower dose; in one case the pain forced the use of intravenous therapy after one dose, and in the other case the pain was mild and the patient was treated for 20 days. We concluded that moxalactam was effective in the treatment of the types of infections included in this study and produced few adverse reactions.
Insights
Moxalactam effectively treated various infections in hospitalized patients, including endometritis and skin infections. This antibiotic demonstrated good tolerability with few adverse reactions, making it a viable treatment option.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Hospitalized patients often present with diverse and severe infections.
- Moxalactam is a newer generation antibiotic with a broad spectrum of activity.
- Evaluating the efficacy and safety of novel antibiotics is crucial for clinical practice.
Purpose of the Study:
- To assess the efficacy of moxalactam in treating various infections in hospitalized patients.
- To evaluate the safety and tolerability profile of moxalactam therapy.
- To determine appropriate dosing and duration of moxalactam treatment based on infection type and patient response.
Main Methods:
- A noncomparative trial involving 67 hospitalized patients with various infections.
- Moxalactam administered intravenously or intramuscularly at doses ranging from 3 to 12 g/day.
- Treatment duration varied from 2 to 42 days, guided by clinical response.
Main Results:
- Moxalactam demonstrated effectiveness in treating endometritis, chorioamnionitis, skin and soft tissue infections, osteomyelitis, pneumonia, urinary tract infections, arthritis, sepsis, endocarditis, and peritonitis.
- Four treatment failures and one superinfection were reported.
- Adverse reactions were minimal, including three cases of allergic reactions and two instances of prolonged coagulation times in patients with severe underlying conditions. Pain on intramuscular injection was also noted.
Conclusions:
- Moxalactam is an effective antibiotic for a range of serious infections encountered in hospitalized patients.
- The drug is generally well-tolerated, with a low incidence of significant adverse effects.
- Moxalactam offers a valuable therapeutic option with a favorable safety profile for managing complex infections.